215 related articles for article (PubMed ID: 17114003)
21. Preliminary studies of new proteasome inhibitors in the tumor targeting approach: synthesis and in vitro cytotoxicity.
Vivier M; Jarrousse AS; Bouchon B; Galmier MJ; Auzeloux P; Sauzieres J; Madelmont JC
J Med Chem; 2005 Oct; 48(21):6731-40. PubMed ID: 16220988
[TBL] [Abstract][Full Text] [Related]
22. Screening for selective small molecule inhibitors of the proteasome using activity-based probes.
Bogyo M
Methods Enzymol; 2005; 399():609-22. PubMed ID: 16338384
[TBL] [Abstract][Full Text] [Related]
23. A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome.
van Swieten PF; Samuel E; Hernández RO; van den Nieuwendijk AM; Leeuwenburgh MA; van der Marel GA; Kessler BM; Overkleeft HS; Kisselev AF
Bioorg Med Chem Lett; 2007 Jun; 17(12):3402-5. PubMed ID: 17442566
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo.
Zinser E; Rössner S; Littmann L; Lüftenegger D; Schubert U; Steinkasserer A
Immunobiology; 2009; 214(9-10):843-51. PubMed ID: 19628298
[TBL] [Abstract][Full Text] [Related]
25. Proteolytic mechanisms underlying mitochondrial degradation in the ocular lens.
Zandy AJ; Bassnett S
Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):293-302. PubMed ID: 17197546
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of proteasome activity sensitizes human granulosa tumor cells to TRAIL-induced cell death.
Woods DC; Liu HK; Nishi Y; Yanase T; Johnson AL
Cancer Lett; 2008 Feb; 260(1-2):20-7. PubMed ID: 18031928
[TBL] [Abstract][Full Text] [Related]
27. Retro hydrazino-azapeptoids as peptidomimetics of proteasome inhibitors.
Aubin S; Martin B; Delcros JG; Arlot-Bonnemains Y; Baudy-Floc'h M
J Med Chem; 2005 Jan; 48(1):330-4. PubMed ID: 15634028
[TBL] [Abstract][Full Text] [Related]
28. Two-step labeling of endogenous enzymatic activities by Diels-Alder ligation.
Willems LI; Verdoes M; Florea BI; van der Marel GA; Overkleeft HS
Chembiochem; 2010 Aug; 11(12):1769-81. PubMed ID: 20623570
[TBL] [Abstract][Full Text] [Related]
29. [Selective effect of epidermal growth factor on the endoribonuclease activity of different subpopulations of proteasomes from A431 cell line. Specificity of extracellular proteasome population].
Kulichkova VA; Mittenberg AG; Evteeva IN; Toktarova MV; Tsimokha AS; Volkova IV; Ermolaeva IuB; Gauze LN; Konstantinova IM
Tsitologiia; 2004; 46(6):525-30. PubMed ID: 15341128
[TBL] [Abstract][Full Text] [Related]
30. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome.
Groll M; Götz M; Kaiser M; Weyher E; Moroder L
Chem Biol; 2006 Jun; 13(6):607-14. PubMed ID: 16793518
[TBL] [Abstract][Full Text] [Related]
31. The role of proteasome in malignant diseases.
Moran E; Nencioni A
J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.
Zaman F; Menendez-Benito V; Eriksson E; Chagin AS; Takigawa M; Fadeel B; Dantuma NP; Chrysis D; Sävendahl L
Cancer Res; 2007 Oct; 67(20):10078-86. PubMed ID: 17942942
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells.
Meissner M; Reichenbach G; Stein M; Hrgovic I; Kaufmann R; Gille J
Cancer Res; 2009 Mar; 69(5):1976-84. PubMed ID: 19223539
[TBL] [Abstract][Full Text] [Related]
34. Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
Rydzewski RM; Burrill L; Mendonca R; Palmer JT; Rice M; Tahilramani R; Bass KE; Leung L; Gjerstad E; Janc JW; Pan L
J Med Chem; 2006 May; 49(10):2953-68. PubMed ID: 16686537
[TBL] [Abstract][Full Text] [Related]
35. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.
Fissolo N; Kraus M; Reich M; Ayturan M; Overkleeft H; Driessen C; Weissert R
Eur J Immunol; 2008 Sep; 38(9):2401-11. PubMed ID: 18792018
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibition by peptide-semicarbazones.
Leban J; Blisse M; Krauss B; Rath S; Baumgartner R; Seifert MH
Bioorg Med Chem; 2008 Apr; 16(8):4579-88. PubMed ID: 18313310
[TBL] [Abstract][Full Text] [Related]
37. Vinyl ester-based cyclic peptide proteasome inhibitors.
Baldisserotto A; Marastoni M; Fiorini S; Pretto L; Ferretti V; Gavioli R; Tomatis R
Bioorg Med Chem Lett; 2008 Mar; 18(6):1849-54. PubMed ID: 18294845
[TBL] [Abstract][Full Text] [Related]
38. Acetylene functionalized BODIPY dyes and their application in the synthesis of activity based proteasome probes.
Verdoes M; Hillaert U; Florea BI; Sae-Heng M; Risseeuw MD; Filippov DV; van der Marel GA; Overkleeft HS
Bioorg Med Chem Lett; 2007 Nov; 17(22):6169-71. PubMed ID: 17888658
[TBL] [Abstract][Full Text] [Related]
39. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
Chen D; Cui QC; Yang H; Barrea RA; Sarkar FH; Sheng S; Yan B; Reddy GP; Dou QP
Cancer Res; 2007 Feb; 67(4):1636-44. PubMed ID: 17308104
[TBL] [Abstract][Full Text] [Related]
40. Aaptamine, an alkaloid from the sponge Aaptos suberitoides, functions as a proteasome inhibitor.
Tsukamoto S; Yamanokuchi R; Yoshitomi M; Sato K; Ikeda T; Rotinsulu H; Mangindaan RE; de Voogd NJ; van Soest RW; Yokosawa H
Bioorg Med Chem Lett; 2010 Jun; 20(11):3341-3. PubMed ID: 20451377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
